Medication info
Yuhan MMET Sustained Release Tablet 25/1000 mg (Empagliflozin, Metformin)

Yuhan MMET Sustained Release Tablet 25/1000 mg (Empagliflozin, Metformin)

Prescription medicationTabletOral
Ingredient · strength
Empagliflozin›25mg / 1 tabletMetformin Hydrochloride›1000mg / 1 tablet
Manufacturer / importer
Yuhan Corporation
Appearance
Pink oval film-coated sustained release tablet
Packaging
30 tablets/bottle
Approval status
Active

MFDS item code 202501954 · Approved 2025.07.29 · Insurance code 642106340

Summary

Main use
Improvement of glycemic control in adults with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
For antidiabetic therapy, determine the dose of this drug based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily dose of each component: empagliflozin 25mg and metformin hydrochloride extended-release 2000mg. Take this drug once daily in the evening with a meal to reduce gastrointestinal adverse reactions caused by metformin. To reduce gastrointestinal adverse reactions associated with metformin use, increase the dose of metformin hydrochloride gradually. To maintain the extended-release properties, swallow this drug whole; do not split, crush, grind, or chew it. ⦁ For patients who do not achieve adequate glycemic control with metformin alone or in combination with other drugs such as insulin, the recommended initial total daily dose when starting this drug is empagliflozin 10 mg and the patient's current metformin dose. If empagliflozin 10 mg is well tolerated and additional glycemic control is needed, the dose may be increased to empagliflozin 25mg. ⦁ Patients switching from combination therapy with empagliflozin and metformin to this drug should receive their previous doses of empagliflozin and metformin. When switching from immediate-release to extended-release metformin, glycemic control should be closely monitored and the dose adjusted appropriately. ⦁ When this drug is co-administered with a sulfonylurea or insulin, consider reducing the dose of the sulfonylurea or insulin to reduce the risk of hypoglycemia (see Precautions for Use, 4. Adverse Reactions and 6. Interactions). Renal impairment As dose adjustment based on renal function is required, assessment of renal function is recommended before starting this drug and periodically thereafter. No dose adjustment is necessary in patients with mild renal impairment [creatinine clearance (CrCl) ≧ 60 mL/min or estimated glomerular filtration rate (eGFR) ≧ 60 mL/min/1.73 m2]. In patients with moderate renal impairment [CKD stage 3A, creatinine clearance (CrCl) ≧ 45 mL/min and <60mL/min or estimated glomerular filtration rate (eGFR) ≧ 45 mL/min/1.73m2 and <60 mL/min/1.73m2] who tolerate treatment well and have no other conditions that may increase the risk of lactic acidosis, this drug may be used with adjustment of the metformin hydrochloride dose as follows. - The starting dose of extended-release metformin hydrochloride is 500 mg or 750 mg once daily; therefore, treatment should not be initiated with this drug. The maximum daily dose of metformin hydrochloride is 1000 mg. If creatinine clearance (CrCl) decreases to below 45 ml/min or estimated glomerular filtration rate (eGFR) decreases to below 45 ml/min/1.73m2, discontinue this drug immediately. Older adults In patients aged 75 years and older, consider renal function and the risk of volume depletion.

Ingredients

Manufacturer
Yuhan Corporation

Efficacy & effects

Improvement of glycemic control in adults with type 2 diabetes mellitus

  • Type 2 diabetes
  • impaired blood glucose control
  • cardiovascular diseases
View approved original text

This medication helps improve blood glucose control in adults with type 2 diabetes by combining Empagliflozin and Metformin. It is used as an adjunct to diet and exercise therapy, and can be taken by those whose blood glucose is not well controlled. Additionally, for patients with cardiovascular diseases, expert clinical trial information should be referenced regarding the risk of cardiovascular events. Overall, this medication is effectively used for diabetes management and blood glucose improvement.

How to take

Adult dose

For antidiabetic therapy, determine the dose of this drug based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily dose of each component: empagliflozin 25mg and metformin hydrochloride extended-release 2000mg. Take this drug once daily in the evening with a meal to reduce gastrointestinal adverse reactions caused by metformin. To reduce gastrointestinal adverse reactions associated with metformin use, increase the dose of metformin hydrochloride gradually. To maintain the extended-release properties, swallow this drug whole; do not split, crush, grind, or chew it. ⦁ For patients who do not achieve adequate glycemic control with metformin alone or in combination with other drugs such as insulin, the recommended initial total daily dose when starting this drug is empagliflozin 10 mg and the patient's current metformin dose. If empagliflozin 10 mg is well tolerated and additional glycemic control is needed, the dose may be increased to empagliflozin 25mg. ⦁ Patients switching from combination therapy with empagliflozin and metformin to this drug should receive their previous doses of empagliflozin and metformin. When switching from immediate-release to extended-release metformin, glycemic control should be closely monitored and the dose adjusted appropriately. ⦁ When this drug is co-administered with a sulfonylurea or insulin, consider reducing the dose of the sulfonylurea or insulin to reduce the risk of hypoglycemia (see Precautions for Use, 4. Adverse Reactions and 6. Interactions). Renal impairment As dose adjustment based on renal function is required, assessment of renal function is recommended before starting this drug and periodically thereafter. No dose adjustment is necessary in patients with mild renal impairment [creatinine clearance (CrCl) ≧ 60 mL/min or estimated glomerular filtration rate (eGFR) ≧ 60 mL/min/1.73 m2]. In patients with moderate renal impairment [CKD stage 3A, creatinine clearance (CrCl) ≧ 45 mL/min and <60mL/min or estimated glomerular filtration rate (eGFR) ≧ 45 mL/min/1.73m2 and <60 mL/min/1.73m2] who tolerate treatment well and have no other conditions that may increase the risk of lactic acidosis, this drug may be used with adjustment of the metformin hydrochloride dose as follows. - The starting dose of extended-release metformin hydrochloride is 500 mg or 750 mg once daily; therefore, treatment should not be initiated with this drug. The maximum daily dose of metformin hydrochloride is 1000 mg. If creatinine clearance (CrCl) decreases to below 45 ml/min or estimated glomerular filtration rate (eGFR) decreases to below 45 ml/min/1.73m2, discontinue this drug immediately. Older adults In patients aged 75 years and older, consider renal function and the risk of volume depletion.

Precautions

This medication is used for the treatment of diabetes and contains two components, Empagliflozin and Metformin. There are several important precautions to consider when taking this medication. Firstly, due to the Metformin component, there is a rare risk of severe side effect known as lactic acidosis, which occurs when excess lactic acid builds up in the body, leading to a dangerous condition. Lactic acidosis can be life-threatening, so if symptoms appear, immediate medical attention is necessary. Moreover, caution is required when taken with other diabetes medications like insulin or sulfonylureas, as this can lead to severe hypoglycemia. This medication should not be used in patients with severely impaired kidney function, acute infections, dehydration, severe heart issues, or type 1 diabetes. Additionally, it should be discontinued prior to examinations using contrast agents and not resumed until kidney function is confirmed to be normal post-examination. Pregnant women or those who may become pregnant, individuals with poor liver function, and those who consume excessive alcohol should also avoid this medication. This medication may increase urine output, so individuals at risk of dehydration should closely monitor their fluid status, and elderly patients or those with decreased kidney function should use this with extra caution. During use, urinary tract infections or genital infections may occur, and if related symptoms appear, immediate consultation with a physician is necessary. Furthermore, Metformin can reduce vitamin B12 levels, so it is advisable to monitor vitamin B12 status during prolonged use. This medication should be swallowed whole; do not chew or crush it, and it is normal for the tablet shell to appear in the stool. Lastly, if there are abrupt changes in body condition or unusual symptoms during the course of taking this medication, it is essential to consult healthcare professionals, and regular monitoring of kidney function and blood glucose levels is important.

Side effects

  • Severe lactic acidosis
  • severe hypoglycemia
  • hypoglycemia
  • urinary tract infection
  • genital infection
  • increased urination
  • decreased and deficiency of Vitamin B12
  • ketoacidosis
  • lactic acidosis
  • decreased fluid volume
Show 165 more
  • nausea
  • vomiting
  • diarrhea
  • abdominal pain
  • loss of appetite
  • constipation
  • abnormal liver function tests
  • hepatitis
  • dysgeusia
  • itching
  • rash
  • urticaria
  • erythema
  • angioedema
  • dysuria
  • interstitial nephritis
  • thirst
  • increased serum lipids
  • increased serum creatinine
  • decreased glomerular filtration rate
  • nausea
  • malaise
  • gastric ulcer
  • colitis
  • ischemic colitis
  • gastrointestinal bleeding
  • chronic gastritis
  • constipation
  • gastritis
  • abdominal discomfort
  • anal incontinence
  • dry mouth
  • gastrointestinal disorders
  • gastroesophageal reflux disease
  • oral discomfort
  • salivary gland pain
  • headache
  • dizziness
  • cerebral infarction
  • sensory loss
  • postural dizziness
  • insomnia
  • anxiety
  • depression
  • sleep disorders
  • fever
  • vascular stent stenosis
  • vascular stent thrombosis
  • chest pain
  • asthenia
  • peripheral edema
  • facial edema
  • peripheral swelling
  • chills
  • strange sensations
  • edema
  • pain
  • pain at the puncture site
  • elevated alanine aminotransferase
  • elevated aspartate aminotransferase
  • weight loss
  • weight gain
  • abnormal electrocardiogram
  • decreased hemoglobin
  • increased hemoglobin
  • positive Helicobacter test
  • positive urine red blood cells
  • ureteral stones
  • acute kidney injury
  • chronic kidney disease
  • hematuria
  • overactive bladder
  • renal mass
  • urinary retention
  • urinary pain
  • abnormal urine
  • vulvar pruritus
  • benign prostatic hyperplasia
  • erectile dysfunction
  • atrophic vaginitis
  • cervical dysplasia
  • cervical inflammation
  • scrotal pain
  • sexual dysfunction
  • vaginal discharge
  • hypoglycemia
  • decreased appetite
  • obesity
  • next-day effect
  • diabetes
  • hyperlipidemia
  • hyponatremia
  • dermoid cyst
  • seborrheic dermatitis
  • atopic dermatitis
  • diabetic foot
  • nummular eczema
  • heat rash
  • sebaceous gland hyperplasia
  • lumbar spinal canal stenosis
  • myalgia
  • limb pain
  • musculoskeletal chest pain
  • arthralgia
  • cervical canal stenosis
  • fibromyalgia
  • flank pain
  • fracture pain
  • muscle weakness
  • musculoskeletal pain
  • osteoarthritis
  • osteoporosis
  • rotator cuff syndrome
  • astigmatism
  • cataract
  • allergic conjunctivitis
  • blurred vision
  • corneal abrasion
  • glaucoma
  • macular fibrosis
  • ocular discomfort
  • conjunctival congestion
  • pathological myopia
  • retinal detachment
  • retinal crystals
  • retinal vein occlusion
  • tear retinal detachment
  • eyelid swelling
  • visual impairment
  • vitreous floaters
  • vitreous hemorrhage
  • nasal bleeding
  • asthma
  • exertional dyspnea
  • wet cough
  • allergic rhinitis
  • persistent sputum
  • cough
  • nasal bleeding
  • allergic rhinitis
  • limb injuries
  • skin laceration
  • contusion
  • rib fracture
  • concussion
  • corneal abrasion
  • falls
  • hand fracture
  • iliotibial band syndrome
  • open globe injury
  • pelvic fracture
  • road traffic accident
  • splenic injury
  • sternum fracture
  • angina
  • palpitations
  • Prinzmetal angina
  • coronary artery disease
  • tachycardia
  • atherosclerosis
  • deep vein thrombosis
  • diabetic vascular disease
  • peripheral arterial occlusive disease
  • unstable angina
  • anxiety

Not everyone experiences these, and they can vary from person to person.

Storage

This medication may be sensitive to air or moisture, so it should be stored in a tightly sealed container. The storage temperature should be maintained at room temperature between 1 and 30 degrees Celsius. This will help preserve the efficacy of the medication over time.

Appearance and packaging

Appearance

Pink oval film-coated sustained release tablet

Package unit

30 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.